Downregulation of DHRS9 is associated with poor prognosis in oral squamous cell carcinoma

Pathology. 2018 Oct;50(6):642-647. doi: 10.1016/j.pathol.2018.06.002. Epub 2018 Aug 24.

Abstract

Oral squamous cell carcinoma (OSCC) has a high potential for local invasion and nodal metastasis. Therefore, early detection and elucidation of the detailed molecular mechanisms underlying OSCC are essential. Dehydrogenase/reductase member 9 (DHRS9) is downregulated in recurrent OSCC. Although DHRS9 is reported to act as a tumour suppressor in several malignancies, its expression in OSCC cells is unknown. In this study, we examined DHRS9 expression immunohistochemically in specimens from a sample of 98 OSCC patients. Reduced DHRS9 expression was observed in 68 of 98 patients (69.4%) with OSCC. A significant association was found between low DHRS9 expression and local progression (T factor) (p = 0.0135). Furthermore, patients with low DHRS9 expression had a significantly poorer prognosis than those with high DHRS9 expression (p = 0.0443). In multivariate analysis using the Cox proportional hazards model, decreased DHRS9 expression strongly correlated with worse prognosis. The study findings suggest that DHRS9 might be a useful diagnostic and prognostic marker for OSCC.

Keywords: DHRS9; oral cancer; prognosis; tumour suppressor.

MeSH terms

  • 3-Hydroxysteroid Dehydrogenases / biosynthesis*
  • Adult
  • Aged
  • Aged, 80 and over
  • Biomarkers, Tumor / analysis*
  • Carcinoma, Squamous Cell / mortality
  • Carcinoma, Squamous Cell / pathology*
  • Disease-Free Survival
  • Down-Regulation
  • Female
  • Head and Neck Neoplasms / mortality
  • Head and Neck Neoplasms / pathology*
  • Humans
  • Kaplan-Meier Estimate
  • Male
  • Middle Aged
  • Mouth Neoplasms / mortality
  • Mouth Neoplasms / pathology*
  • Prognosis
  • Proportional Hazards Models
  • Squamous Cell Carcinoma of Head and Neck

Substances

  • Biomarkers, Tumor
  • 3-Hydroxysteroid Dehydrogenases
  • DHRS9 protein, human